USRE30985E - Serum-free cell culture media - Google Patents

Serum-free cell culture media Download PDF

Info

Publication number
USRE30985E
USRE30985E US06232020 US23202081A USRE30985E US RE30985 E USRE30985 E US RE30985E US 06232020 US06232020 US 06232020 US 23202081 A US23202081 A US 23202081A US RE30985 E USRE30985 E US RE30985E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
milligrams per
sub
acid
medium
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06232020
Inventor
Oscar A. Cartaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0037Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/33Insulin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/395Thyroid hormones

Abstract

A serum-less medium for use in the growth of cells. The medium is an improved aqueous culture media of the MEM type comprising thyroxin, insulin, and Vitamin A. Hydrocortisone and essential fatty acids may also be advantageously used, as may effective quantities of Vitamin E. Surfactants are used to make the vitamins and any fatty acids available for cell growth. This aqueous media may also comprise cell-growth-enhancing quantities of biotin and folic acids.

Description

RELATED APPLICATION

This application is a continuation-in-part of application Ser. No. 951,500 filed Oct. 6, 1978 which was a continuation-in-part of application Ser. No. 866,338 filed Jan. 1, 1978, both now abandoned.

BACKGROUND OF THE INVENTION

This invention relates to a novel cell growing medium and novel process for growing living cells.

Over the years there has been a substantial amount of effort directed to the problem of providing a versatile and efficacious culture media from reproducible, fully-characterized components. This "ideal" approach is frequently compromised with respect to the "fully characterized" nature of the components. For example, much work has been done (e.g. as described in U.S. Pat. Nos. 3,128,228 by J. Michl and 3,953,290 by K. Uthne) describing the use of serum of blood fractions in cell culture media. However, these fractions have some of the disadvantages of whole serum and other bulk protein sources. They are not as fully characterized as is desirable; that is, they will differ from batch to batch and introduce unknown variables in the media. Such variables can affect the growth of cells and can do so in wholly umpredictable ways.

Other workers have recognized the value of culture media which is free of serum and other bulk protein supplements which can interfere with cell replication. To date, some of these attempts have proved partially successful. Although the media developed in each case has serious limitations.

Thus, Torney et al in U.S. Pat. No. 3,887,930 and U.S. Pat. No. 4,055,460 describes a media containing a particulate resin which provides an undesirable substrate on which cells can grow and from which their removal can be difficult.

The work described by Bower, Arthur and Fine, Propagation of mouse mammary tumor cell lines and production of mouse mammary tumor virus in a serum free media, in In Vitro (Pages 558-563, Volume 12, No. 8, 1976), utilizes a media containing considerable amounts of ethyl alcohol and lipids. The high volatility of ethyl alcohol (much higher than that of the acqueous media), which is used in this media to disperse the lipids in the acqueous solution, predisposes their media to serious problems. Gradual evaporation of the alcohol must be expected in the conditions to be found in cell culture incubators (about 37° C. with a variable CO2 concentration in the atmosphere), causing their media to separate into a biphasic (lipid-acqueous) mixture. This type of mixture would not be appropriate for most cell culture work, nor would its exact composition be easily regulated. Besides, high concentration of alcohol, by itself, may have undesirable effects upon cell growth in many situations.

Other work, as described by S. T. Donta in "The growth of functional rat glial cells in a serumless medium." in Experimental Cell Research (Pages 119-124, Volume 82, 1973), has succeeded in adapting a single, specialized cell line to grow in a chemically defined media without bulk protein supplementation. However, this media has been unable to support the growth of other cell lines, unless used in combination with albumin. Thus, the media is not versatile unless supplemented with proteins which are not fully characterized.

Still another work, as described in U.S. Pat. No. 4,049,494, relates to processes for growing cells in serum-less media wherein the cells are from cell lines which have been specially adapted to function in the media. Such processes and media, of course, are lacking in broad utility. U.S. Pat. No. 4,072,565 describes the use of protamine zinc insulin in processes limited to short-terms by limitations inherent in the media selected.

Therefore, even after one decides on the ideal of providing a serum-free media, it is a further problem to provide a media with a combination of nutrients versatile with respect to a cell type that can be grown in it. Also, these nutrients, once identified, must be made available to the cells in a controlled fashion, without the introduction of highly volatile components of biphasic mixtures of variable composition. Furthermore, such a media must be free of particulate elements which would introduce unwarranted growth surfaces. Finally, this media should not be supplemented with partially refined bulk protein sources.

SUMMARY OF THE INVENTION

It is a principal object of the invention to provide an improved aqueous culture medium for growing cells.

It is a particular object of the invention to provide a culture medium that is fully characterized and, consequently, subject to accurate replication without dependence on animal blood serums or on other non-characterized materials, e.g. the bulk protein supplements commonly used in the art.

A further object of the invention is to provide a culture media described in the foregoing objects which comprises specific combinations of vitamins, fatty acids, and hormones to enhance cellular growth and which is substantially free of volatile or particulate components.

Still another object of the invention is to provide an improved basic culture media, one which is not necessarily optimized with respect to specific nutrients, but which is a substantial improvement over minimum essential media (MEM), including those of the zinc option type, known to the art.

A further object of the invention is to provide cell growth media of improved shelf life and versatility.

Another object of the invention is to provide an improved process utilizing the valuable features of the culture media of the invention.

Further objects of the invention include providing specific combinations of cell-growth materials in such a way as to make them readily available to growing cells over an extended period of time.

Other objects of the invention will be obvious to those skilled in the art on their reading this disclosure.

The above objects have been substantially achieved by (a) the development of an improved basic culture media of the MEM-zinc option type. In the more advantageous forms of the invention, an improved basic media is enhanced with hormones such as thyroxine, and insulin and Vitamin A. It is also advantageous to add hydrocortisone and essential fatty acids such as linoleic, linolenic and arachidonic acids. Vitamin E is also a desirable additive. In each case an acceptably water-dispersable, physiologically-equivalent compound such as physiologically equivalent salts, isomers, homologues, polymers, or other derivatives may be utilized. In general, the physiological equivalents are well known to the art.

It is to be emphasized that the process and media of the instant invention is useful with a wide variety of cells without special selective breeding products to build up a special adaption to the serum. Moreover, the cell growth can be prolonged over periods of three months or more in many advantageous modes of the invention.

The Basic Medium

One basic medium, found advantageous by itself and also advantageous for use as a base for a selective augmentation, is formed with substantial quantities of amino acids, biotin and folic acid. This basic medium, fortified to achieve an improved amino acid profile and fortified with the indicated vitamins, provides a growth culture media of improved versatility and performance.

To form the preferred growth media of the invention, the following are to be added to the fortified basic medium as described above.

Thyroxine: preferably T4 but T3 could also be used. The material is available in many commercial forms, including salt forms. Quantities of T4 from 0.01 to 0.03 micrograms per liter are desirable.

Insulin: A quantity of about 4 milligrams per liter is used.

Hydrocortsone: Again, this material is available in many forms. What is essential is to have a cortisone-active nucleus. A quantity of from about 0.075 to 0.3 milligrams per liter is preferred.

Essential Fatty Acids: The preferred acids are linoleic, linolenic and arachidonic. Although not water soluble, these materials are so emulsified with an appropriate surfactant as to become distributed in the aqueous medium in such a way that their molecules are readily available to the cell-growing population even in the preferred aqueous growth media. A quantity of from about 2.5 to 15 milligrams per liter is required.

Vitamin E and Vitamin A: Vitamin A is preferably used in a quantity of from about 0.1 to 0.4 milligrams per liter. Vitamin E is preferably used in quantities of from about 7.5 to 30 milligrams per liter.

Surfactants: In a sufficient quantity to disperse the Vitamins and fatty acids and, thus, provides means to assure availability of the fatty acids and vitamins to the growing cells. A polysorbate 20 is advantageously used.

It is presently believed that the thyroxin, insulin and Vitamin A should be utilized in all embodiments of the invention. Hydrocortisone and essential fatty acids are highly advantageous. Vitamin E is believed to be important in contributing to the versatility of the invention.

One of the problems with developing a serumless tissue culture media comes with passaging, e.g. transferring, the cells between vessels. Proteolytic enzymes (trypsin or the like) will not be neutralized by this kind of media, since a factor present in serum is active in the neutralization process, and can result in damage or death to the cells. Appropriate physical or mechanical means to detach and passage the cells are, therefore, preferable. If proteolytic enzymes become necessary for whatever reason for effective cell detachment, it is suggested that the cells should be washed before replating in media containing enzyme inhibitors which are commercially available. In any event, it is desirable to avoid cell-damaging quantities of enzymes like trypsin in effecting transfer of these serum-free cell populations.

It is to be understood that the various components of the growth media of the invention can be obtained from natural sources when it is convenient to do so. For example, the fatty acids could be made available as processed vegetable oils, e.g. soybean or safflower oil. In such cases, it is necessary to so process the natural material as to remove any substantial quantities of unknown proteinaceous substances.

Although, it is usually preferable to use a zinc-option-type minimum essential medium (MEM) it is possible to achieve a substantial number of the advantages using the invention by appropriate modification of such commercial products known to those skilled in the art, such as Medium 199 Eagle's Basal Medium, Eagle's Minimum Essential Medium or the like.

Illustrative Examples of the Invention

It is, of course, to be understood that the following examples are intended to be illustrative and that numerous changes can be made in the reactants, precise proportions, and conditions set forth therein without departing from the spirit of the invention as defined in the appended claims.

A fortified basic medium formula is prepared according to good preparatory procedures as known in the art.

______________________________________Item          Amount (milligrams per liter)______________________________________L-alanine     8.9L-asparagine  75.0L-aspartic acid         13.0L-glutamic acid         14.7L-glycine     7.5L-proline     11.5L-serine      52.5L-arginine HCl         196.52L-cystine     37.2L-glutamine   584.0L-histidine HCl         65.0L-isoleucine  80.88L-leucine     160.88L-lysine      112.38L-methionine  23.30L-phenyl-alanine         50.15L-threonine   74.18L-tryptophan  15.61L-valine      71.4L-tyrosine    45.9CaCl          200KCl           400.[.MgCl6H.sub.2 O.]..Iadd.MgCl.sub.2 . 6H.sub.2 O.Iaddend.         183MgSO.sub.4 7H.sub.2 O         12NaCl          6800NaH.sub.2 PO.sub.4 H.sub.2 O         150NaHCO.sub.3   sufficient to adjust to a Ph of 7.4phenol red    10glucose       2000Na pyruvate   110biotin        1.0D-calcium pantothenate         1.0choline Cl    56.0folic acid    1.0inositol      36.0nicotinamide  1.0pyridoxal HCl 1.0riboflavin    0.1thiamine      1.0B.sub.12      1.36folinic acid  1.0DL thioctic acid         0.20putrescine HCl         0.16linoleic      0.084FeCl.sub.3 6H.sub.2 O         0.54ZnSO.sub.4 7H.sub.2 O         0.14insulin       4.00HEPES buffer solution         2380.0______________________________________ Distilled water to make a total of 1 liter

In general, the quantities of ingredients set out above can be modified by about plus-or-minus 20%; which modifications are to be construed to be "about" those required to function as does the listed formula.

HEPES buffer solution is the name given to buffer solutions containing N-2-hydroxyethyl piperazine-N'-2-ethanesulfonic acid. It has a pKa value of about 7.5.

The aforesaid basic media was used in Example 1 set forth below.

EXAMPLE 1

Table 1C illustrates the advantageous characteristics of this basic medium when it is compared to

A. the improved fortified basic media of the invention both with and without the addition of 10% fetal calf serum;

B. a commerically available zinc-option-bearing MEM formula sold under the trade designation IMEMZO & HEPES by Associated Biomedic Systems, Inc., of Buffalo, N.Y. Again, the comparison was carried out with and without augmentation of the formula with 10% fetal calf serum.

The drawing is indicative of the cell growth in terms of thimidine radioactive count (TRC) as follows:

              TABLE 1C______________________________________Growth Media and Cell History                      Count______________________________________IMEMZO & HEPES, no serum-cell line                      nilIMEMZO & HEPES, no serum initial culture                      nilBasic Media of Invention, no serum-initial culture                       1,533Basic Media of Invention, no serum-cell line culture                      54,672Basic Media of Invention, serum-cell line culture                      20,825Basic Media of Invention, serum-initial culture                       8,293______________________________________

"Initial culture" is used to define the primary tumor cells. "Cell line" is used to define cells grown on tissue culture flask for a minimum of five passages.

It will be readily seen that the Basic Media of the invention is superior in cell-line culturing procedures, not only to media with different fully-characterized profiles (IMEMZO) but to itself when fetal calf serum is incorporated therein.

The results disclosed in Example 1 were obtained according to the following procedure:

The tumor cells used in this experiment were rhabdomyosarcoma of mice, Balb-C strain, produced in the laboratory by the intramuscular injection of methylcholanthrene in experimental animals. The tumor was observed to form within several weeks of injection. This tumor was subcultured and kept by serial passage within a line of Balb-C mice and in serum supplemented tissue culture media by different researchers.

A suspension of viable cells were injected subcutaneously in Balb-C mice (from Charles River Breeding Labs) in a concentration of 1,000,000 viable cells per injection. Tumor growth was carefully monitored in these mice.

Cells obtained from these tumors may be classified in several different fashions. "Primary tumor cells" define cells obtained by the disperion of the tumor grown anew, fresh, in a Balb-C mouse. These cells were separated from the tumor, by the use of standard trypsinization techniques. Trypsin was neutralized with serum and the cells were washed before further use. Their viability was assayed by the trypan blue technique. These cells are labelled as "Primary Tumor Cells."

Cell lines were cultured in tissue culture media from these primary tumor cells by using basic media, as described in the body of this disclosure, e.g. Example 1. However, this basic media used to establish the cell lines contained 10% (by volume) of fetal calf serum. Prior to use of these cell lines, the cells were again dispersed by the cold-media technique described below and their viability checked by the trypan blue technique. These cells are referred to herein as "cell lines."

Transferring of the cells between vessels, in multipassages work is accomplished by adding cold media (about 4° C.) to the flask followed by shaking and dispersion by vortexing. In this way the cells are cold shocked and readily released for transfer .[.way the cells are cold shocked and readily released for transfer .]. to a new vessel and a new passage

The following procedure is used to test for the activity of the different growth media formulations:

The growth of cells was estimated by the amount of incorporation of radioactively labelled (tritium labelled) thimidine. Thimidine is incorporated by growing cells for the manufacture of DNA. Thus, the amount of radioactivity incorporated into growing cells incubated in radiactively labelled thimidine directly approximates the growth that has taken place within the cell culture. Cells were grown in this fashion using each of stock-IMEMZO and the basic medium of the invention. For each medium, experiments were carried out with media containing 10% (by volume) fetal calf serum and media containing no serum.

Incorporation of radioactively labelled thimidine by primary tumor cells and cell lines grown in stock-IMEMZO media either with or without fetal calf serum supplementation, is nil or not significantly different than the background radioactive count. Primary cells grown in basic media with no serum supplementation shows an incorporation of 1,533 radioactive counts. Primary cells grown in basic media with 10% fetal calf serum supplementation showed an incorporation of 8,293 counts.

The cell line, as described above, is a primary tumor cell that has been serially grown in vitro for a minimum of 5 passages. A passage being defined as that period of time it takes for the cells to form a monolayer. This is followed by dispersion of this monolayer and reculturing of cell aliguots in a fresh flask.

Testing of the cell lines resulted in markedly different results. The cell line grown in stock-IMEMZO media with or without serum supplementation again was unable to incorporate radioactivity to any appreciable extent. The cell line grown in basic media with no serum supplementation showed an incorporation of 54,672 counts on the average. The cell line grown in basic media supplemented with 10% fetal calf serum showed an incorporation of only 20,825 counts.

In all cases, the cells were incubated for three days at 37° C. in a 5% CO2 atmosphere before they were exposed to radioactively labelled thimidine for 12 hours and then counted again. In each case, quadruplicate culutures of 105 viable cells were carried out by use of a microtiter plate culturing system. These cells were processed for counting with an automatic harvesting machine and counted in a Searle liquid scintillation counter.

The numbers given for incorporation of radio active counts represent the average number of counts per minute per culture, counted by the liquid scintillation apparatus. All the cells present in each culture were harvested and the total radioactive content of the complete population of cells in each culture yielded the radioactive counts expressed above as an average. Each different type of culture (determined by the media used, the cell type and the presence or absence of fetal calf serum in the media) yielded, therefore, its own average count.

The following conclusions may be derived from the experiments above:

1. Stock-IMEMZO, either with or without serum supplementation, is unable to support the growth of these cells in vitro.

2. Basic medium with a 10% fetal calf serum supplementation is better than the same media without serum supplementation in supporting the growth of primary cells in vitro.

3. Basic medium with no serum supplementation supports the in vitro growth of cell lines up to 250% better than basic medium with 10% serum supplementation.

Basic medium without serum supplementation seems to be clearly superior to the same medium with 10% fetal calf serum supplementation in growing cell lines in vitro. Thereby it provides a medium able to sustain cell lines in vitro without the use of serum or other bulk biological products.

To test the abiliy of the basic medium to sustain the growth of cell lines for extended periods of time, the cell lines described above were grown in basic medium, free of serum supplementation, for a period of five months. The changeover to serumless medium was accomplished gradually, over 2 weeks. The cells were observed to clump initially, but soon afterwards they regained their normal morphology and were observed to form monolayers and grow as well as the control cell lines kept in media supplemented with 10% fetal calf serum. Thus, the basic medium was clearly successful in supporting the growth of these cell lines. At this point it was decided to terminate these experiments with methylcholanthrene induced rhabdomyosarcoma cell lines and to start testing various other cell lines for their growth in this media.

EXAMPLE 2--The Growth Media

To the above basic media were added the following:

______________________________________Item              Amount______________________________________thyroxine         0.02 micrograms per literinsulin           4 milligrams per literhydrocortisone    .[.1.5.]. .Iadd.0.15.Iaddend.             milligrams per literlinoleic acid     5.0 milligrams per literlinolenic acid    5.0 milligrams per literarachidonic acid  5.0 milligrams per litersurfactant, emulsifier*             110 milligrams per literVitamin E         20 milligrams per literVitamin A         0.25 milligrams per liter______________________________________

The surfactant is a micelle-forming material sold by Supelco Co. under the trade designation Tween 20. The material is characterized by its ability to emulsify, or isolate and expose, molecules of fatty acids in small micelle-type structures thereby making them readily dispersible in aqueous solutions and available to the growing cells. Any other surfactant which achieves this effect with a reasonable concentration and is not otherwise detrimental to cell growth may also be utilized.

The procedure of Example 1 is used to demonstrate the advantage of the above-described culture media. Excellent results are achieved with cell lines.

EXAMPLE 3

The following certified cell lines, all available in the American-type Culture Collection at Rockville, Md., are also advantageously grown in the growth medium of Example 2, and then counted according to the procedure set forth therein:

MRC--Human embryonic lung cell line.

L929--Mouse fibrosarcoma line.

Vero--African green monkey kidney line.

It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which might be said to fall therebetween.

Claims (13)

What is claimed is:
1. .[.An MEM zinc option.]. .Iadd.A cell culturing .Iaddend.medium wherein the amino acid profile is about as follows:
______________________________________Item         Amount (milligrams per liter)______________________________________L alanine    8.9L asparagine 75.0L aspartic acid        13.0L glutamic acid        14.7L glycine    7.5L proline    11.5L serine     52.5L arginine HCl        196.52L cystine    37.2L glutamine  584.0L histidine HCl        65.0L isoleucine 80.88L leucine    160.88L lysine     112.38L methionine 23.30L phenyl-alanine        50.15L threonine  74.18L tryptophan 15.61L valine     71.4L tyrosine   45.9______________________________________
2. .[.An MEM zinc option.]. .Iadd.A .Iaddend.medium, as defined in claim 1, wherein said medium is augmented with cell growth promoting quantities of biotin and folic acid.
3. A culture media as defined in claim 1 further comprising
______________________________________Thyroxine       0.01 to 0.03 micrograms per literInsulin         4 milligrams per literHydrocortisone  0.075 to 0.3 milligrams per literEssential Fatty Acids           2.5 to 15 milligrams per literVitamin A       0.1 to 0.4 milligrams per literVitamin E       7.5 to 30 milligrams per literSurfactants     Sufficient quantity to disperse           vitamins and fatty acids.______________________________________
4. A culture media as defined in claim 2 further comprising
______________________________________Thyroxine       0.01 to 0.03 micrograms per literInsulin         4 milligrams per literHydrocortisone  0.075 to 0.3 milligrams per literEssential Fatty Acids           2.5 to 15 milligrams per literVitamin A       0.1 to 0.4 milligrams per literVitamin E       7.5 to 30 milligrams per literSurfactants     Sufficient quantity to disperse           vitamins and fatty acids.______________________________________
5. A culture media as defiined in claim 3 wherein said surfactant is a polysorbate 20.
6. A culture media as defined in claim 1 further comprising
______________________________________Item              Amount______________________________________thyroxine         0.02 micrograms per literinsulin           4 milligrams per literhydrocortisone    .[.1.5.]. .Iadd.0.15.Iaddend.             milligrams per literlinoleic acid     5.0 milligrams per literlinolenic acid    5.0 milligrams per literarachidonic acid  5.0 milligrams per litersurfactant, emulsifier             110 milligrams per literVitamin E         20 milligrams per literVitamin A         0.25 milligrams per liter______________________________________
7. An aqueous culture media for use in cell growth having about the following formula:
______________________________________Item          Amount (milligrams per liter)______________________________________L alanine     8.9L asparagine  75.0L aspartic acid         13.0L glutamic acid         14.7L glycine     7.5L proline     11.5L serine      52.5L arginine HCl         196.52l cystine     37.2L glutamine   584.0L histidine HCl         65.0L isoleucine  80.88L leucine     160.88L lysine      112.38L methionine  23.30L phenyl-alanine         50.15L threonine   74.18L tryptophan  15.61L valine      71.4L tyrosine    45.9CaCl          200KCl           400.[.MgCl6H.sub.2 O.]..Iadd.MgCl.sub.2 . 6H.sub.2 O.Iaddend.         183MgSO.sub.4 7H.sub.2 O         12NaCl          6800NaH.sub.2 PO.sub.4 H.sub.2 O         150phenol red    10glucose       2000Na pyruvate   110biotin        1.0D-calcium pantothenate         1.0choline Cl    56.0folic acid    1.0inositol      36.0nicotinamide  1.0pyridoxal HCl 1.0riboflavin    0.1thiamine      1.0B.sub.12      1.36folinic acid  1.0DL thioctic acid         0.20putrescine HCl         0.16linoleic      0.084FeCl.sub.3 6H.sub.2 O         0.54ZnSO.sub.4 7H.sub.2 O         0.14insulin       4.00HEPES buffer solution         2380.0NaHCO.sub.3   sufficient to adjust to a pH of         about 7.4______________________________________ Distilled water to make a total of 1 liter
8. A culture media as defined in claim 7 further comprising
______________________________________Thyroxine       0.01 to 0.03 micrograms per literInsulin         4 milligrams per literHydrocortisone  0.075 to 0.3 milligrams per literEssential Fatty Acids           2.5 to 15 milligrams per literVitamin A       0.1 to 0.4 milligrams per literVitamin E       7.5 to 30 milligrams per literSurfactants     Sufficient quantity to disperse           vitamins and fatty acids.______________________________________
9. A medium as defined in claims 3, 4, or 8 wherein said essential fatty acids are predominantly comprised of linoleic acid, linolenic acid and arachindonic acid.
10. A medium as defined in claims 1, 2, 7, 3, 4, 8, 5 or 6 wherein said medium is maintained substantially free of cell-damaging quantities of proteolytic enzymes.
11. An improved process for growing lines of living cells comprising the steps of growing said cells in a growth medium, through at least two passages, said medium .[.an.]. .Iadd.a modified .Iaddend.MEM .[.zinc option type.]. medium having about the following amino acid profile:
______________________________________Item         Amount (milligrams per liter)______________________________________L alanine    8.9L asparagine 75.0L aspartic acid        13.0L glutamic acid        14.7L glycine    7.5L proline    11.5L serine     52.5L arginine HCl        196.52L cystine    37.2L glutamine  584.0L histidine HCl        65.0L isoleucine 80.88L leucine    160.88L lysine     112.38L methionine 23.30L phenyl-alanine        50.15L threonine  74.18L tryptophan 15.61L valine     71.4L tyrosine   45.9______________________________________
12. A process as defined in claim 11 wherein said medium comprises effective amounts of additional nutrients as follows:
biotin
folic acid
Thyroxine
Insulin
Hydrocortisone
Essential Fatty Acids
Vitamin A
Vitamin E
Surfactants
13. A process as defined in claims 11 or 12, wherein transfer of cells from one passage to another is primarily effected by use of physical means and without use of cell-harming quantities of proteolytic enzymes.
US06232020 1978-01-01 1981-02-06 Serum-free cell culture media Expired - Lifetime USRE30985E (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US86633878 true 1978-01-01 1978-01-01
US06232020 USRE30985E (en) 1978-01-01 1981-02-06 Serum-free cell culture media

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06232020 USRE30985E (en) 1978-01-01 1981-02-06 Serum-free cell culture media

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US05951500 Continuation-In-Part 1978-10-16
US05969590 Reissue US4205126A (en) 1978-01-01 1978-12-14 Serum-free cell culture media

Publications (1)

Publication Number Publication Date
USRE30985E true USRE30985E (en) 1982-06-29

Family

ID=26925613

Family Applications (1)

Application Number Title Priority Date Filing Date
US06232020 Expired - Lifetime USRE30985E (en) 1978-01-01 1981-02-06 Serum-free cell culture media

Country Status (1)

Country Link
US (1) USRE30985E (en)

Cited By (324)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532948A1 (en) * 1982-09-15 1984-03-16 Collaborative Res Inc Supplements and combination to cell growth media, and process for their manufacture
EP0112174A2 (en) * 1982-12-16 1984-06-27 Immunex Corporation Serum-free cell culture medium and process for making same
FR2557886A1 (en) * 1984-01-06 1985-07-12 Inst Nat Sante Rech Med Media for the production and culture of secretory cells or their hybridomas
US4757018A (en) 1985-02-11 1988-07-12 Hazleton Biotechnologies, Inc. Myeloma cell lines and uses thereof
EP0283942A2 (en) * 1987-03-24 1988-09-28 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
WO1989001028A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation Serum free media for the growth of insect cells and expression of products thereby
WO1989001027A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation Lipid microemulsions for culture media
WO1990003429A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Lipid microemulsions for culture media
WO1990007007A1 (en) * 1988-12-14 1990-06-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Cell culture medium for human liver epithelial cell line
EP0390327A2 (en) * 1989-02-27 1990-10-03 Eli Lilly And Company improved tissue culture method
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5372943A (en) * 1987-07-24 1994-12-13 Cetus Corporation Lipid microemulsions for culture media
FR2715028A1 (en) * 1994-01-17 1995-07-21 Charrueau Christine Soln for preserving organs, tissues etc contg amino acids
US5529920A (en) * 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
EP0786257A1 (en) 1992-06-03 1997-07-30 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6270987B1 (en) 1997-01-31 2001-08-07 Genentech, Inc. O-fucosyltransferase
US20030077739A1 (en) * 2001-08-27 2003-04-24 Genentech, Inc. System for antibody expression and assembly
US20030225023A1 (en) * 2002-04-10 2003-12-04 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
US20040006018A1 (en) * 1996-02-14 2004-01-08 Genentech, Inc. Cardiotrophin and uses therefor
US20040115714A1 (en) * 2001-04-06 2004-06-17 Georgetown University Gene BRCC-2 and diagnostic and therapeutic uses thereof
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
US20040248218A1 (en) * 2001-04-06 2004-12-09 Georgetown University Gene SCC-112 and diagnostic and therapeutic uses thereof
US20050166274A1 (en) * 2002-06-07 2005-07-28 Dorothy French Compositions and methods for the diagnosis and treatment of tumor
WO2005093064A1 (en) 2004-03-29 2005-10-06 Galpharma Co., Ltd. Novel galectin 9 modification protein and use thereof
US20060008878A1 (en) * 2004-04-07 2006-01-12 The University Of Chicago Monomeric red fluorescent proteins
EP1630168A2 (en) 1997-08-27 2006-03-01 Chiron Corporation Molecular mimetics of meningococcal B peptides
US20060069019A1 (en) * 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
EP1650220A2 (en) 1997-04-07 2006-04-26 Genentech, Inc. Anti-VEGF antibodies
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US20060182716A1 (en) * 2004-08-09 2006-08-17 Jin Hong Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US20060204473A1 (en) * 2004-08-09 2006-09-14 Blatt Lawrence M Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
WO2006102547A2 (en) 2005-03-23 2006-09-28 Bio-Rad Laboratories, Inc. Method for purifying proteins
US20060239990A1 (en) * 2003-04-30 2006-10-26 Nabel Elizabeth G Protein Arginine N-Methyltransferase 2 (PRMT-2)
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
US20070020725A1 (en) * 2000-12-14 2007-01-25 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2007056470A2 (en) 2005-11-08 2007-05-18 Genentech, Inc. Neuropilin antagonists
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20070202552A1 (en) * 2005-12-02 2007-08-30 Genentech, Inc. Binding Polypeptides and Uses Thereof
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
US20080075719A1 (en) * 2004-04-16 2008-03-27 Genentech, Inc. Method for Augmenting B Cell Depletion
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2008070344A2 (en) 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
EP1950300A2 (en) 1998-11-18 2008-07-30 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1953229A2 (en) 1998-10-15 2008-08-06 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
US20080187966A1 (en) * 2003-01-23 2008-08-07 Genentech, Inc. Antibodies and methods for making and using them
US20080195366A1 (en) * 2004-05-06 2008-08-14 Eigenbrot Charles W Crystal structure of the hepatocyte growth factor and methods of use
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP1958965A2 (en) 1997-08-25 2008-08-20 Genentech, Inc. Agonist antibodies to a musk receptor, and their therapeutic uses
EP1961813A2 (en) 1998-12-16 2008-08-27 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
US20080213277A1 (en) * 2007-02-02 2008-09-04 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US20080233118A1 (en) * 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
US7442520B2 (en) 2001-04-06 2008-10-28 Georgetown University Gene BRCC-3 and diagnostic and therapeutic uses thereof
EP1985701A2 (en) 2000-01-10 2008-10-29 Novartis Vaccines and Diagnostics, Inc. Genes differentially expressed in breast cancer
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20080292639A1 (en) * 2005-01-24 2008-11-27 Amgen Inc. Humanized Anti-Amyloid Antibody
EP2011873A2 (en) 1994-05-27 2009-01-07 Genentech, Inc. Tumor necrosis factor receptor-associated factors
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2014303A2 (en) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
US20090023602A1 (en) * 2003-08-01 2009-01-22 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2009033024A1 (en) 2007-09-05 2009-03-12 Genentech, Inc. Biologically active c-terminal arginine-containing peptides
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
EP2039768A1 (en) 1996-11-13 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Mutant forms of Fas ligand and uses thereof
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
US7537885B2 (en) 2003-05-09 2009-05-26 Lifeblood Medical Inc. Composition for maintaining organ and cell viability
US20090136483A1 (en) * 2007-05-30 2009-05-28 Sabbadini Roger A Compositions and Methods for Binding Lysophosphatidic Acid
EP2065467A2 (en) 2001-02-22 2009-06-03 Genentech, Inc. Anti-interferon-alpha antibodies
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US20090232804A1 (en) * 2008-01-23 2009-09-17 Glenmark Pharmaceuticals, S.A., Humanized antibodies specific for von willebrand factor
US20090253135A1 (en) * 2007-11-30 2009-10-08 Ansell Stephen M POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
EP2112167A2 (en) 1999-06-25 2009-10-28 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20100034814A1 (en) * 2007-05-30 2010-02-11 Sabbadini Roger A Compositions and methods for binding lysophosphatidic acid
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
WO2010060095A1 (en) 2008-11-24 2010-05-27 Bristol-Myers Squibb Company Bispecific egfr/igfir binding molecules
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
US20100158904A1 (en) * 2008-11-06 2010-06-24 Glenmark Pharmaceuticals, S.A. Treatment with anti-alpha2 integrin antibodies
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2010111367A1 (en) 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2241622A2 (en) 1994-03-18 2010-10-20 Genentech, Inc. Human trk receptors and their derivatives
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2248829A1 (en) 2003-05-30 2010-11-10 Genentech, Inc. Treatment with anti-VEGF antibodies
EP2263691A1 (en) 2002-07-15 2010-12-22 Genentech, Inc. Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2275448A2 (en) 2003-12-19 2011-01-19 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2011008959A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Enhancement of cellular production through mechanotransduction
US20110020784A1 (en) * 2007-11-01 2011-01-27 Glick Benjamin S Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US20110020319A1 (en) * 2007-10-26 2011-01-27 Sabbadini Roger A Use of anti- sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
EP2301580A1 (en) 1997-04-07 2011-03-30 Genentech, Inc. Anti-VEGF antibodies
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2011038302A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Novel modulators
EP2308974A2 (en) 1999-10-14 2011-04-13 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
EP2311960A2 (en) 2001-08-29 2011-04-20 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
US20110091477A1 (en) * 2009-10-19 2011-04-21 Genentech, Inc. Modulators of hepatocyte growth factor activator
US20110091952A1 (en) * 2009-07-23 2011-04-21 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US20110104252A1 (en) * 2001-01-26 2011-05-05 Georgetown University Anti-apoptotic gene scc-s2 and diagnostic and therapeutic uses thereof
WO2011053538A1 (en) 2009-10-27 2011-05-05 Exxonmobil Research And Engineering Company Multi-stage processes and control thereof
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011057239A2 (en) 2009-11-09 2011-05-12 Abbott Laboratories Secretory protein biomarkers for high efficiency protein expression
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
EP2322556A1 (en) 2004-09-03 2011-05-18 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
EP2325208A1 (en) 2005-12-15 2011-05-25 Genentech, Inc. Polyubiquitin antibodies
WO2011063277A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2332996A1 (en) 2002-09-11 2011-06-15 Genentech, Inc. Protein Purification
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
US20110150865A1 (en) * 2006-10-12 2011-06-23 Genentech, Inc. Antibodies to lymphotoxin-alpha
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
WO2011103105A1 (en) 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
EP2361931A1 (en) 2004-07-20 2011-08-31 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2011104604A2 (en) 2010-02-23 2011-09-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2364997A2 (en) 1999-01-15 2011-09-14 Genentech, Inc. Polypeptide variants with altered effector function
EP2377527A1 (en) 2007-01-22 2011-10-19 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
WO2011130354A1 (en) 2010-04-13 2011-10-20 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011140086A2 (en) 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
EP2402373A2 (en) 2006-01-05 2012-01-04 Genentech, Inc. Anti-EphB4 Antibodies and Methods Using Same
WO2012021648A1 (en) 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
EP2420512A2 (en) 2003-08-01 2012-02-22 Genentech, Inc. Anti-VEGF antibodies
EP2423231A2 (en) 2006-08-18 2012-02-29 Novartis AG PRLR-specific antibody and uses thereof
EP2426150A1 (en) 2006-06-30 2012-03-07 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012040041A1 (en) 2010-09-20 2012-03-29 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
EP2436781A1 (en) 2007-02-22 2012-04-04 Genentech, Inc. Methods for detecting inflammatory bowel disease
WO2012045275A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with aplastic anemia
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012045273A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
WO2012045279A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
EP2446904A2 (en) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
WO2012068106A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP2468772A2 (en) 2006-03-16 2012-06-27 Genentech, Inc. Antibodies to EGFL7 and methods for their use
EP2468776A2 (en) 2007-02-09 2012-06-27 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2474557A2 (en) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
WO2012106587A1 (en) 2011-02-04 2012-08-09 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
EP2503341A2 (en) 2006-11-14 2012-09-26 Genentech, Inc. Modulators of Neuronal Regeneration
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
EP2511257A2 (en) 2005-03-21 2012-10-17 ViroBay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
WO2012142515A2 (en) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
EP2535346A1 (en) 2005-08-31 2012-12-19 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP2548967A2 (en) 2006-09-21 2013-01-23 The Regents of The University of California Aldehyde tags, uses thereof in site-specific protein modification
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
EP2565206A2 (en) 2007-10-30 2013-03-06 Genentech, Inc. Antibody purification by cation exchange chromatography
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2013052963A1 (en) 2011-10-07 2013-04-11 Nico Corporation Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications
WO2013055958A1 (en) 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
EP2586788A1 (en) 2007-07-09 2013-05-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2013067029A2 (en) 2011-10-31 2013-05-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
WO2013096322A1 (en) 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
EP2614839A2 (en) 2006-04-05 2013-07-17 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2623516A2 (en) 2005-12-02 2013-08-07 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
EP2641618A2 (en) 2007-07-16 2013-09-25 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
EP2644205A1 (en) 2007-04-12 2013-10-02 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
EP2657253A2 (en) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
WO2013163294A1 (en) 2012-04-24 2013-10-31 Genentech, Inc. Cell culture compositions and methods for polypeptide production
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013192395A1 (en) 2012-06-20 2013-12-27 Genentech, Inc. Methods for inactivation of viruses and bacteria in cell culture media
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
US8664471B2 (en) 2001-12-19 2014-03-04 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
EP2727936A1 (en) 2006-11-22 2014-05-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014144198A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
WO2014160495A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
WO2014160507A1 (en) 2013-03-13 2014-10-02 Genzyme Corporation Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
WO2014158231A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP2845866A1 (en) 2006-10-27 2015-03-11 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2848625A1 (en) 2008-08-14 2015-03-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2851372A1 (en) 2007-11-30 2015-03-25 Genentech, Inc. Anti-VEGF antibodies
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
US9000132B2 (en) 2013-03-15 2015-04-07 Diadexus, Inc. Lipoprotein-associated phospholipase A2 antibody compositions and methods of use
EP2857516A1 (en) 2000-04-11 2015-04-08 Genentech, Inc. Multivalent antibodies and uses therefor
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015095418A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
WO2015143156A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
WO2015148736A1 (en) 2014-03-25 2015-10-01 Genentech, Inc. Methods of preparing a poloxamer for use in cell culture medium
US9170262B2 (en) 2010-06-16 2015-10-27 Abbvie, Inc. Comparison of protein samples
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9200070B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
EP2962697A1 (en) 2006-11-27 2016-01-06 diaDexus, Inc. Ovr110 antibody compositions and methods of use
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
US9266950B2 (en) 2009-10-20 2016-02-23 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
EP3011970A2 (en) 2009-10-22 2016-04-27 F. Hoffmann-La Roche AG Modulation of axon degeneration
EP3023497A1 (en) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
WO2016156537A1 (en) 2015-03-31 2016-10-06 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
US9465029B2 (en) 2004-04-16 2016-10-11 Glaxo Group Limited Methods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activity
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2016171980A1 (en) 2015-04-24 2016-10-27 Bristol-Myers Squibb Company Polypeptides targeting hiv fusion
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9546215B2 (en) 2013-12-09 2017-01-17 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
US9562097B2 (en) 2011-07-01 2017-02-07 Genentech, Inc. Use of anti-CD83 agonist antibodies for treating autoimmune diseases
WO2017024062A1 (en) 2015-08-04 2017-02-09 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
EP3141560A2 (en) 2008-05-06 2017-03-15 Genentech, Inc. Affinity matured crig variants
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017053617A1 (en) 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3211008A1 (en) 2008-08-29 2017-08-30 F. Hoffmann-La Roche AG Cross-reactive and bispecific anti-il-17a/f antibodies
US9759726B2 (en) 2014-03-27 2017-09-12 Academia Sinica Reactive labelling compounds and uses thereof
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US9816981B2 (en) 2007-03-23 2017-11-14 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
WO2017196902A2 (en) 2016-05-10 2017-11-16 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
WO2017210302A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
WO2017218977A2 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US9975957B2 (en) 2014-03-31 2018-05-22 Genentech, Inc. Anti-OX40 antibodies and methods of use
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US9988611B2 (en) 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10010611B2 (en) 2013-03-13 2018-07-03 Genentech, Inc. Antibody formulations
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10087255B2 (en) 2015-04-07 2018-10-02 Alector Llc Anti-sortilin antibodies and methods of use thereof
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10111951B2 (en) 2017-08-29 2018-10-30 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Willmer-Cells & Tissues in Culture, vol. 1, (1965), pp. 99-102. *

Cited By (479)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532948A1 (en) * 1982-09-15 1984-03-16 Collaborative Res Inc Supplements and combination to cell growth media, and process for their manufacture
EP0112174A2 (en) * 1982-12-16 1984-06-27 Immunex Corporation Serum-free cell culture medium and process for making same
EP0112174A3 (en) * 1982-12-16 1985-05-15 Immunex Corporation Serum-free cell culture medium and process for making same
FR2557886A1 (en) * 1984-01-06 1985-07-12 Inst Nat Sante Rech Med Media for the production and culture of secretory cells or their hybridomas
US4757018A (en) 1985-02-11 1988-07-12 Hazleton Biotechnologies, Inc. Myeloma cell lines and uses thereof
EP0283942A2 (en) * 1987-03-24 1988-09-28 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
EP0283942A3 (en) * 1987-03-24 1989-11-15 W.R. Grace & Co.-Conn. (A Connecticut Corp.) Basal nutrient medium for cell culture
US5372943A (en) * 1987-07-24 1994-12-13 Cetus Corporation Lipid microemulsions for culture media
WO1989001028A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation Serum free media for the growth of insect cells and expression of products thereby
WO1989001027A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation Lipid microemulsions for culture media
WO1990003429A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Lipid microemulsions for culture media
US5529920A (en) * 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
US5342777A (en) * 1988-12-14 1994-08-30 The United States Of America As Represented By The Secretary Of The Dept. Of Health And Human Services Cell culture medium for human liver epithelial cell line
WO1990007007A1 (en) * 1988-12-14 1990-06-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Cell culture medium for human liver epithelial cell line
EP0390327A3 (en) * 1989-02-27 1990-11-14 Eli Lilly And Company Improved tissue culture method
EP0390327A2 (en) * 1989-02-27 1990-10-03 Eli Lilly And Company improved tissue culture method
US5110722A (en) * 1989-11-09 1992-05-05 Cryolife, Inc. Cell, tissue or organ storage solution
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0786257A1 (en) 1992-06-03 1997-07-30 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
FR2715028A1 (en) * 1994-01-17 1995-07-21 Charrueau Christine Soln for preserving organs, tissues etc contg amino acids
EP2241622A2 (en) 1994-03-18 2010-10-20 Genentech, Inc. Human trk receptors and their derivatives
EP2011873A2 (en) 1994-05-27 2009-01-07 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US20040006018A1 (en) * 1996-02-14 2004-01-08 Genentech, Inc. Cardiotrophin and uses therefor
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
EP2039768A1 (en) 1996-11-13 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Mutant forms of Fas ligand and uses thereof
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
US6270987B1 (en) 1997-01-31 2001-08-07 Genentech, Inc. O-fucosyltransferase
EP3260468A1 (en) 1997-04-07 2017-12-27 Genentech, Inc. Anti-vegf antibodies
EP2338915A2 (en) 1997-04-07 2011-06-29 Genentech, Inc. Anti-VEGF antibodies
EP2336190A2 (en) 1997-04-07 2011-06-22 Genentech, Inc. Anti-VEGF antibodies
EP2301580A1 (en) 1997-04-07 2011-03-30 Genentech, Inc. Anti-VEGF antibodies
EP1650220A2 (en) 1997-04-07 2006-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1958965A2 (en) 1997-08-25 2008-08-20 Genentech, Inc. Agonist antibodies to a musk receptor, and their therapeutic uses
EP1630168A2 (en) 1997-08-27 2006-03-01 Chiron Corporation Molecular mimetics of meningococcal B peptides
EP1953229A2 (en) 1998-10-15 2008-08-06 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
EP1950300A2 (en) 1998-11-18 2008-07-30 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1961813A2 (en) 1998-12-16 2008-08-27 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
EP2364997A2 (en) 1999-01-15 2011-09-14 Genentech, Inc. Polypeptide variants with altered effector function
EP2366713A2 (en) 1999-01-15 2011-09-21 Genentech, Inc. Polypeptide variants with altered effector function
EP2386574A2 (en) 1999-01-15 2011-11-16 Genentech, Inc. Polypeptide variants with altered effector function
EP2112167A2 (en) 1999-06-25 2009-10-28 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
US20110183375A1 (en) * 1999-08-27 2011-07-28 Life Technologies Corporation Metal binding compounds and their use in cell culture medium compositions
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US20040214327A1 (en) * 1999-08-27 2004-10-28 Epstein David A. Metal binding compounds and their use in cell culture medium compositions
EP2308974A2 (en) 1999-10-14 2011-04-13 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
EP1757311A2 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1985701A2 (en) 2000-01-10 2008-10-29 Novartis Vaccines and Diagnostics, Inc. Genes differentially expressed in breast cancer
EP2857516A1 (en) 2000-04-11 2015-04-08 Genentech, Inc. Multivalent antibodies and uses therefor
EP2014303A2 (en) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
US20070020725A1 (en) * 2000-12-14 2007-01-25 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
US20070065909A1 (en) * 2000-12-14 2007-03-22 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
US20110104252A1 (en) * 2001-01-26 2011-05-05 Georgetown University Anti-apoptotic gene scc-s2 and diagnostic and therapeutic uses thereof
EP2065467A2 (en) 2001-02-22 2009-06-03 Genentech, Inc. Anti-interferon-alpha antibodies
EP2292301A2 (en) 2001-02-22 2011-03-09 Genentech, Inc. Anti-interferon-alpha antibodies
US7253272B2 (en) 2001-04-06 2007-08-07 Georgetown University Gene BRCC-2 and diagnostic and therapeutic uses thereof
US20040115714A1 (en) * 2001-04-06 2004-06-17 Georgetown University Gene BRCC-2 and diagnostic and therapeutic uses thereof
US7442520B2 (en) 2001-04-06 2008-10-28 Georgetown University Gene BRCC-3 and diagnostic and therapeutic uses thereof
US20040248218A1 (en) * 2001-04-06 2004-12-09 Georgetown University Gene SCC-112 and diagnostic and therapeutic uses thereof
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000148A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of prostate cancer
EP2000545A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US9688775B2 (en) 2001-08-27 2017-06-27 Genentech, Inc. System for antibody expression and assembly
US20070015244A1 (en) * 2001-08-27 2007-01-18 Genentech, Inc. System for antibody expression and assembly
US20030077739A1 (en) * 2001-08-27 2003-04-24 Genentech, Inc. System for antibody expression and assembly
US20060246542A1 (en) * 2001-08-27 2006-11-02 Genentech, Inc. System for antibody expression and assembly
EP2311960A2 (en) 2001-08-29 2011-04-20 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
EP2153843A1 (en) 2001-09-18 2010-02-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2151244A1 (en) 2001-09-18 2010-02-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8664471B2 (en) 2001-12-19 2014-03-04 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20030225023A1 (en) * 2002-04-10 2003-12-04 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
US20050166274A1 (en) * 2002-06-07 2005-07-28 Dorothy French Compositions and methods for the diagnosis and treatment of tumor
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
EP2263691A1 (en) 2002-07-15 2010-12-22 Genentech, Inc. Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
EP3388452A2 (en) 2002-09-11 2018-10-17 Genentech, Inc. Protein purification
EP2332996A1 (en) 2002-09-11 2011-06-15 Genentech, Inc. Protein Purification
US20080187966A1 (en) * 2003-01-23 2008-08-07 Genentech, Inc. Antibodies and methods for making and using them
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
US20060239990A1 (en) * 2003-04-30 2006-10-26 Nabel Elizabeth G Protein Arginine N-Methyltransferase 2 (PRMT-2)
US7537885B2 (en) 2003-05-09 2009-05-26 Lifeblood Medical Inc. Composition for maintaining organ and cell viability
EP2251355A1 (en) 2003-05-30 2010-11-17 Genentech, Inc. Treatment with anti-VEGF antibodies
EP2248829A1 (en) 2003-05-30 2010-11-10 Genentech, Inc. Treatment with anti-VEGF antibodies
EP2311875A1 (en) 2003-05-30 2011-04-20 Genentech, Inc. Treatment with anti-VEGF antibodies
US20090023602A1 (en) * 2003-08-01 2009-01-22 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2420512A2 (en) 2003-08-01 2012-02-22 Genentech, Inc. Anti-VEGF antibodies
EP2301568A1 (en) 2003-11-17 2011-03-30 Genentech, Inc. Antibody against IRTA2 for the treatment of tumour of hematopoietic origin
EP2295073A1 (en) 2003-11-17 2011-03-16 Genentech, Inc. Antibody against CD22 for the treatment of tumour of hematopoietic origin
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP2275448A2 (en) 2003-12-19 2011-01-19 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2005093064A1 (en) 2004-03-29 2005-10-06 Galpharma Co., Ltd. Novel galectin 9 modification protein and use thereof
US7671185B2 (en) 2004-04-07 2010-03-02 The University Of Chicago Monomeric red fluorescent proteins
US7250298B2 (en) 2004-04-07 2007-07-31 The University Of Chicago Monomeric red fluorescent proteins
US7910714B2 (en) 2004-04-07 2011-03-22 The University Of Chicago Monomeric red fluorescent proteins
US20100184954A1 (en) * 2004-04-07 2010-07-22 The University Of Chicago Monomeric red fluorescent proteins
US20060008878A1 (en) * 2004-04-07 2006-01-12 The University Of Chicago Monomeric red fluorescent proteins
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US9465029B2 (en) 2004-04-16 2016-10-11 Glaxo Group Limited Methods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activity
US20080075719A1 (en) * 2004-04-16 2008-03-27 Genentech, Inc. Method for Augmenting B Cell Depletion
US20080195366A1 (en) * 2004-05-06 2008-08-14 Eigenbrot Charles W Crystal structure of the hepatocyte growth factor and methods of use
US20060069019A1 (en) * 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
US20080293923A1 (en) * 2004-05-06 2008-11-27 Christian Wiesmann Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use
US7754458B2 (en) 2004-05-06 2010-07-13 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use
US20110012894A1 (en) * 2004-05-06 2011-01-20 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use
EP2361931A1 (en) 2004-07-20 2011-08-31 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060182716A1 (en) * 2004-08-09 2006-08-17 Jin Hong Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20060204473A1 (en) * 2004-08-09 2006-09-14 Blatt Lawrence M Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
EP2322556A1 (en) 2004-09-03 2011-05-18 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
US20100277473A1 (en) * 2004-12-10 2010-11-04 Eigenbrot Jr Charles W Crystal structure of hepatocyte growth factor activator complexed with kunitz domain inhibitor
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
EP2230517A1 (en) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110 antibody compositions and methods of use
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US20080292639A1 (en) * 2005-01-24 2008-11-27 Amgen Inc. Humanized Anti-Amyloid Antibody
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US20090028795A1 (en) * 2005-02-25 2009-01-29 Ulevitch Richard J NOD1 as an Anti-Tumor Agent
EP2511257A2 (en) 2005-03-21 2012-10-17 ViroBay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
WO2006102547A2 (en) 2005-03-23 2006-09-28 Bio-Rad Laboratories, Inc. Method for purifying proteins
EP3214095A1 (en) 2005-05-12 2017-09-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2399932A1 (en) 2005-05-12 2011-12-28 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
US20080233118A1 (en) * 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
EP2535346A1 (en) 2005-08-31 2012-12-19 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP3181575A1 (en) 2005-08-31 2017-06-21 The Regents of The University of California Cellular libraries of peptide sequences (clips) and methods of using the same
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP2570434A2 (en) 2005-11-08 2013-03-20 Genentech, Inc. Neuropilin antagonists
WO2007056470A2 (en) 2005-11-08 2007-05-18 Genentech, Inc. Neuropilin antagonists
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
EP3023497A1 (en) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2623516A2 (en) 2005-12-02 2013-08-07 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
EP3006466A2 (en) 2005-12-02 2016-04-13 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
US20070202552A1 (en) * 2005-12-02 2007-08-30 Genentech, Inc. Binding Polypeptides and Uses Thereof
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
EP2325208A1 (en) 2005-12-15 2011-05-25 Genentech, Inc. Polyubiquitin antibodies
EP3309170A1 (en) 2005-12-15 2018-04-18 Genentech, Inc. Polyubiquitin antibodies
EP3156418A1 (en) 2006-01-05 2017-04-19 Genentech, Inc. Anti-ephb4 antibodies and methods using same
EP2402373A2 (en) 2006-01-05 2012-01-04 Genentech, Inc. Anti-EphB4 Antibodies and Methods Using Same
EP2093235A1 (en) 2006-02-08 2009-08-26 Alios Biopharma Inc. Hyperglycosylated variants of interferon alfacon-1
EP2468772A2 (en) 2006-03-16 2012-06-27 Genentech, Inc. Antibodies to EGFL7 and methods for their use
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389950A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389949A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389948A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
EP3088410A2 (en) 2006-04-05 2016-11-02 AbbVie Biotechnology Ltd Antibody purification
EP2614839A2 (en) 2006-04-05 2013-07-17 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
EP2447282A2 (en) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
EP2446904A2 (en) 2006-05-30 2012-05-02 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2426150A1 (en) 2006-06-30 2012-03-07 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
EP2423231A2 (en) 2006-08-18 2012-02-29 Novartis AG PRLR-specific antibody and uses thereof
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
EP2548967A2 (en) 2006-09-21 2013-01-23 The Regents of The University of California Aldehyde tags, uses thereof in site-specific protein modification
US8541552B2 (en) 2006-10-12 2013-09-24 Genetech, Inc. Antibodies to lymphotoxin-α
US8216807B2 (en) 2006-10-12 2012-07-10 Genentech, Inc. Antibodies to lymphotoxin-α
US20110150865A1 (en) * 2006-10-12 2011-06-23 Genentech, Inc. Antibodies to lymphotoxin-alpha
US8642740B2 (en) 2006-10-12 2014-02-04 Genentech, Inc. Antibodies to lymphotoxin-alpha
US20110208673A1 (en) * 2006-10-12 2011-08-25 Genentech, Inc. Antibodies to lymphotoxin-alpha
US8222373B2 (en) 2006-10-27 2012-07-17 Lpath, Inc. Humanized antibodies and compositions for binding sphingosine-1-phosphate
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
EP2845866A1 (en) 2006-10-27 2015-03-11 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20090130099A1 (en) * 2006-10-27 2009-05-21 David Williams Humanized antibodies and compositions for binding sphingosine-1-phosphate
WO2008070344A2 (en) 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
EP2503341A2 (en) 2006-11-14 2012-09-26 Genentech, Inc. Modulators of Neuronal Regeneration
EP3156415A1 (en) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
EP2727936A1 (en) 2006-11-22 2014-05-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
EP2962697A1 (en) 2006-11-27 2016-01-06 diaDexus, Inc. Ovr110 antibody compositions and methods of use
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
EP2377527A1 (en) 2007-01-22 2011-10-19 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
US8629250B2 (en) 2007-02-02 2014-01-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US20080213277A1 (en) * 2007-02-02 2008-09-04 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP2468776A2 (en) 2007-02-09 2012-06-27 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
EP2436781A1 (en) 2007-02-22 2012-04-04 Genentech, Inc. Methods for detecting inflammatory bowel disease
US9816981B2 (en) 2007-03-23 2017-11-14 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
EP2644205A1 (en) 2007-04-12 2013-10-02 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
US8158124B2 (en) 2007-05-30 2012-04-17 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20100034814A1 (en) * 2007-05-30 2010-02-11 Sabbadini Roger A Compositions and methods for binding lysophosphatidic acid
US20090136483A1 (en) * 2007-05-30 2009-05-28 Sabbadini Roger A Compositions and Methods for Binding Lysophosphatidic Acid
EP3327026A1 (en) 2007-07-09 2018-05-30 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2586788A1 (en) 2007-07-09 2013-05-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2502937A2 (en) 2007-07-16 2012-09-26 Genentech, Inc. Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use
EP2474557A2 (en) 2007-07-16 2012-07-11 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2641618A2 (en) 2007-07-16 2013-09-25 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
WO2009033024A1 (en) 2007-09-05 2009-03-12 Genentech, Inc. Biologically active c-terminal arginine-containing peptides
EP3241846A1 (en) 2007-10-04 2017-11-08 ZymoGenetics, Inc. B7 family member zb7h6 and related compositions and methods
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
US20110020319A1 (en) * 2007-10-26 2011-01-27 Sabbadini Roger A Use of anti- sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2565206A2 (en) 2007-10-30 2013-03-06 Genentech, Inc. Antibody purification by cation exchange chromatography
EP2840090A1 (en) 2007-10-30 2015-02-25 Genentech, Inc. Antibody purification by cation exchange chromatography
US8679749B2 (en) 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US20110020784A1 (en) * 2007-11-01 2011-01-27 Glick Benjamin S Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
EP2851372A1 (en) 2007-11-30 2015-03-25 Genentech, Inc. Anti-VEGF antibodies
US20090253135A1 (en) * 2007-11-30 2009-10-08 Ansell Stephen M POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
EP3173425A1 (en) 2007-11-30 2017-05-31 Genentech, Inc. Anti-vegf antibodies
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20090232804A1 (en) * 2008-01-23 2009-09-17 Glenmark Pharmaceuticals, S.A., Humanized antibodies specific for von willebrand factor
US8236315B2 (en) 2008-01-23 2012-08-07 Glenmark Pharmaceuticals, S.A. Humanized antibodies specific for von Willebrand factor
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
US9688759B2 (en) 2008-01-25 2017-06-27 Amgen, Inc. Ferroportin antibodies and methods of use
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2574628A1 (en) 2008-01-25 2013-04-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2803675A2 (en) 2008-01-25 2014-11-19 Amgen, Inc Ferroportin antibodies and methods of use
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
EP2657253A2 (en) 2008-01-31 2013-10-30 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP3141560A2 (en) 2008-05-06 2017-03-15 Genentech, Inc. Affinity matured crig variants
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
EP2848625A1 (en) 2008-08-14 2015-03-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP3211008A1 (en) 2008-08-29 2017-08-30 F. Hoffmann-La Roche AG Cross-reactive and bispecific anti-il-17a/f antibodies
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8298531B2 (en) 2008-11-06 2012-10-30 Glenmark Pharmaceuticals, S.A. Treatment with anti-alpha2 integrin antibodies
US20100158904A1 (en) * 2008-11-06 2010-06-24 Glenmark Pharmaceuticals, S.A. Treatment with anti-alpha2 integrin antibodies
EP3029064A1 (en) 2008-11-24 2016-06-08 Bristol-Myers Squibb Company Bispecific egfr/igfir binding molecules
WO2010060095A1 (en) 2008-11-24 2010-05-27 Bristol-Myers Squibb Company Bispecific egfr/igfir binding molecules
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US10000571B2 (en) 2009-03-25 2018-06-19 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US20100291114A1 (en) * 2009-03-25 2010-11-18 Genentech, Inc. Crystal structures and methods using same
US9499623B2 (en) 2009-03-25 2016-11-22 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US9161977B2 (en) 2009-03-25 2015-10-20 F. Hoffmann-La Roche Ag Anti-FGFR3 antibodies and methods using same
US8710189B2 (en) 2009-03-25 2014-04-29 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US8410250B2 (en) 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US20100247531A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
WO2010111367A1 (en) 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
EP2679600A1 (en) 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
US20110117603A1 (en) * 2009-07-15 2011-05-19 Abbott Laboratories Enhancement of cellular production through mechanotransduction
WO2011008959A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Enhancement of cellular production through mechanotransduction
US8765431B2 (en) 2009-07-23 2014-07-01 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
US20110091952A1 (en) * 2009-07-23 2011-04-21 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2957296A1 (en) 2009-09-25 2015-12-23 Xoma (Us) Llc Insulin receptor binding antibodies
WO2011038302A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Novel modulators
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
US8759491B2 (en) 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
WO2011049868A1 (en) 2009-10-19 2011-04-28 Genentech, Inc. Modulators of hepatocyte growth factor activator
US20110091477A1 (en) * 2009-10-19 2011-04-21 Genentech, Inc. Modulators of hepatocyte growth factor activator
US9266950B2 (en) 2009-10-20 2016-02-23 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
US9975948B2 (en) 2009-10-20 2018-05-22 Abbvie, Inc. Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography
EP3037104A1 (en) 2009-10-20 2016-06-29 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
EP3011970A2 (en) 2009-10-22 2016-04-27 F. Hoffmann-La Roche AG Modulation of axon degeneration
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011053538A1 (en) 2009-10-27 2011-05-05 Exxonmobil Research And Engineering Company Multi-stage processes and control thereof
WO2011057239A2 (en) 2009-11-09 2011-05-12 Abbott Laboratories Secretory protein biomarkers for high efficiency protein expression
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
WO2011063277A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
EP3002297A2 (en) 2009-11-30 2016-04-06 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
US9714281B2 (en) 2010-02-18 2017-07-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
WO2011103105A1 (en) 2010-02-18 2011-08-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
US8927693B2 (en) 2010-02-18 2015-01-06 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2848632A1 (en) 2010-02-23 2015-03-18 Sanofi Anti-alpha2 integrin antibodies and their uses
WO2011104604A2 (en) 2010-02-23 2011-09-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US8420098B2 (en) 2010-04-13 2013-04-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to PCSK9
WO2011130354A1 (en) 2010-04-13 2011-10-20 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
US9856309B2 (en) 2010-04-13 2018-01-02 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind PCSK9
US9234027B2 (en) 2010-04-13 2016-01-12 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind PCSK9
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011140086A2 (en) 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Serum albumin binding molecules
US9874562B2 (en) 2010-05-10 2018-01-23 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US9487809B2 (en) 2010-05-28 2016-11-08 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US10011856B2 (en) 2010-05-28 2018-07-03 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011153346A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US9170262B2 (en) 2010-06-16 2015-10-27 Abbvie, Inc. Comparison of protein samples
US9405884B2 (en) 2010-06-16 2016-08-02 Abbvie Inc. Methods and systems for the analysis of protein samples
WO2012021648A1 (en) 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
WO2012040041A1 (en) 2010-09-20 2012-03-29 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
WO2012045275A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with aplastic anemia
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012045273A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
WO2012045279A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068106A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012106587A1 (en) 2011-02-04 2012-08-09 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
EP3144320A1 (en) 2011-04-13 2017-03-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012142515A2 (en) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US9090688B2 (en) 2011-04-27 2015-07-28 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9255143B2 (en) 2011-04-27 2016-02-09 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505834B2 (en) 2011-04-27 2016-11-29 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9562097B2 (en) 2011-07-01 2017-02-07 Genentech, Inc. Use of anti-CD83 agonist antibodies for treating autoimmune diseases
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013052963A1 (en) 2011-10-07 2013-04-11 Nico Corporation Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications
US9862778B2 (en) 2011-10-11 2018-01-09 Genentech, Inc. Assembly of bispecific antibodies
WO2013055958A1 (en) 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
WO2013067029A2 (en) 2011-10-31 2013-05-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9988611B2 (en) 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
WO2013096322A1 (en) 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9957318B2 (en) 2012-04-20 2018-05-01 Abbvie Inc. Protein purification methods to reduce acidic species
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014143184A1 (en) 2012-04-20 2014-09-18 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9346879B2 (en) 2012-04-20 2016-05-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9359434B2 (en) 2012-04-20 2016-06-07 Abbvie, Inc. Cell culture methods to reduce acidic species
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013163294A1 (en) 2012-04-24 2013-10-31 Genentech, Inc. Cell culture compositions and methods for polypeptide production
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
WO2013177118A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of non-human antibodies using protein a affinity chromatography
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014143185A1 (en) 2012-05-24 2014-09-18 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
EP3205715A1 (en) 2012-06-20 2017-08-16 H. Hoffnabb-La Roche Ag Methods for viral inactivation and other adventitious agents
WO2013192395A1 (en) 2012-06-20 2013-12-27 Genentech, Inc. Methods for inactivation of viruses and bacteria in cell culture media
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9290568B2 (en) 2012-09-02 2016-03-22 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014160507A1 (en) 2013-03-13 2014-10-02 Genzyme Corporation Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
US9637534B2 (en) 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
US10010611B2 (en) 2013-03-13 2018-07-03 Genentech, Inc. Antibody formulations
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014160495A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9663810B2 (en) 2013-03-14 2017-05-30 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
US9487810B2 (en) 2013-03-14 2016-11-08 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014158231A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9926583B2 (en) 2013-03-14 2018-03-27 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014144198A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US9000132B2 (en) 2013-03-15 2015-04-07 Diadexus, Inc. Lipoprotein-associated phospholipase A2 antibody compositions and methods of use
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10017732B2 (en) 2013-03-15 2018-07-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9266949B2 (en) 2013-10-18 2016-02-23 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9200069B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9315574B2 (en) 2013-10-18 2016-04-19 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9200070B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
US9546215B2 (en) 2013-12-09 2017-01-17 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015095418A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
WO2015143156A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
WO2015148736A1 (en) 2014-03-25 2015-10-01 Genentech, Inc. Methods of preparing a poloxamer for use in cell culture medium
US9759726B2 (en) 2014-03-27 2017-09-12 Academia Sinica Reactive labelling compounds and uses thereof
US9975957B2 (en) 2014-03-31 2018-05-22 Genentech, Inc. Anti-OX40 antibodies and methods of use
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
WO2016156537A1 (en) 2015-03-31 2016-10-06 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
US10087255B2 (en) 2015-04-07 2018-10-02 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016171980A1 (en) 2015-04-24 2016-10-27 Bristol-Myers Squibb Company Polypeptides targeting hiv fusion
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
WO2017024062A1 (en) 2015-08-04 2017-02-09 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017053617A1 (en) 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
US10113193B2 (en) 2016-03-31 2018-10-30 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
WO2017196902A2 (en) 2016-05-10 2017-11-16 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
WO2017210302A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
WO2017218977A2 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
US10111951B2 (en) 2017-08-29 2018-10-30 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups

Similar Documents

Publication Publication Date Title
Cohen The stimulation of epidermal proliferation by a specific protein (EGF)
Wessells Substrate and nutrient effects upon epidermal basal cell orientation and proliferation
Kallman et al. Fine structure of differentiating mouse pancreatic exocrine cells in transfilter culture
Fryer et al. The in vitro cultivation of tissue and cells of Pacific salmon and steelhead trout
Broome Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo
Daniel et al. Growth of mouse mammary glands in vivo after monolayer culture
Puck et al. Genetics of somatic mammalian cells: III. Long-term cultivation of euploid cells from human and animal subjects
Grobstein Interactive processes in cytodifferentiation
Néchad et al. Development of brown fat cells in monolayer culture: I. Morphological and biochemical distinction from white fat cells in culture
Steinberger et al. Isolation and culture of FSH responsive Sertoli cells
US4016036A (en) Process for serially culturing keratinocytes
Puck et al. Clonal growth in vitro of human cells with fibroblastic morphology: comparison of growth and genetic characteristics of single epithelioid and fibroblast-like cells from a variety of human organs
US5670147A (en) Compositions containing cultured mitotic human stem cells
Emerman et al. Maintenance and induction of morphological differentiation in dissociated mammary epithelium on floating collagen membranes
Nicolas et al. Cell lines derived from teratocarcinomas
Moore et al. RNA synthesis in the mouse oocyte
Sidman Histogenesis of brown adipose tissue in vivo and in organ culture
Tobey Production and Characterization of Mammalian Iſoleucine-Deficient Medium
Cooke et al. Restoration of normal morphology and estrogen responsiveness in cultured vaginal and uterine epithelia transplanted with stroma
Bonney et al. Primary monolayer cultures of adult rat liver parenchymal cells suitable for study of the regulation of enzyme synthesis
US5045454A (en) Serum-free growth medium and use thereof
Merchant et al. Growth of LM strain mouse cells in a chemically defined medium.
Gurdon et al. The transplantation of nuclei from single cultured cells into enucleate frogs' eggs
Echalier et al. In vitrol culture ofDrosophila melanogaster embryonic cells
US5888720A (en) In vitro micro-organs